行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.64倍，行业中值0.36倍。联合医 务市盈率8.41倍，行业排名第10位；其他巨星医疗控股（02393.HK）为0.33倍、京玖康疗（00648.HK） 为0.38倍、永胜医疗（01612.HK）为4.25倍、环球医疗（02666.HK）为4.64倍、瑞慈医疗（01526.HK） 为5.2倍。 资料显示，联合医务集团有限公司成立於1990年,为香港联交所主板上市公司(股份代号722.HK),是香港 及澳门领先的医疗保健平台,30年来一直致力让所有人获得可信任及可负担的服务,从而在不用担忧健康 的考虑下,追求自己的梦想。 联合医务除了为个人提供多元化的医疗保健服务,亦与企业及保险公司保持 紧密合作,为会员设计及管理企业医疗保健福利计划。近年来,联合医务更紧贴国家政策,於内地各主要城 市开展家庭医生培训服务,并与当地社区卫生服务机构携手打造公私营合作的联合医务诊室。 2020年度, 联合医务年就诊人次超过135万。目前联合医务旗下自设及联营的800多家医疗服务机构覆盖香港、澳 门、北京、天津、上海,以及粤港澳大湾区包括广州、深圳、珠海、中山、东莞 ...

资料显示，紫元元控股集团有限公司,香港联合交易所上市企业(股票代码:08223.HK),总部坐落于中国深 圳,分别在北京、杭州、武汉、河南、成都、广州、香港等地设有办事处。 6月16日，截至港股收盘，恒生指数上涨0.7%，报24060.99点。紫元元（08223.HK）收报1.7港元/股， 上涨14.09%，成交量179.8万股，成交额295.3万港元，振幅18.12%。 最近一个月来，紫元元累计跌幅5.7%，今年来累计跌幅6.29%，跑输恒生指数19.11%的涨幅。 财务数据显示，截至2024年12月31日，紫元元实现营业总收入5.52亿元，同比增长10.91%；归母净利 润-5297万元，同比减少463.73%；毛利率15.67%，资产负债率49.94%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-22.06倍，行业中值0.39倍。紫元元 市盈率-11.2倍，行业排名第74位；其他京玖康疗（00648.HK）为0.38倍、巨星医疗控股（02393.HK） 为0.4倍、永胜医疗（01612.HK）为4.39倍、环球医疗（02666.HK ...

Company Overview - Health Road Holdings Limited operates a digital health service platform in China, ranking as the fourth largest by registered personal users and fifth largest by revenue as of 2023 according to Frost & Sullivan [3] - The company has been providing health services on digital platforms since 2001 and expanded to offer enterprise services and digital marketing since 2015, playing a significant role in the digital transformation of the health and wellness industry in China over the past 20 years [3] Financial Performance - As of December 31, 2024, Health Road reported total revenue of 1.201 billion yuan, a year-on-year decrease of 3.51%, while the net profit attributable to shareholders was -268 million yuan, an increase of 13.42% [2] - The gross profit margin stood at 30.47%, and the debt-to-asset ratio was 59.82% [2] Stock Performance - Over the past month, Health Road's stock has increased by 58.77%, and year-to-date, it has surged by 284.17%, outperforming the Hang Seng Index's increase of 19.82% [2] - As of June 13, the stock closed at 55.05 HKD per share, with a trading volume of 4.393 million shares and a turnover of 238 million HKD, showing a volatility of 18.61% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -21.62 times, with a median of 0.39 times [2] - Health Road's P/E ratio is -152.14 times, ranking 54th in the industry, compared to other companies such as Jingjiu Health (0.38 times), Giant Star Medical Holdings (0.4 times), and others [2]

资料显示，隽泰控股有限公司("公司")是一家于百慕大注册成立之有限公司,及其已发行股份于一九九六 年在香港联合交易所有限公司主板上市(股票编号:630)。公司透过其附属公司主要从事制造及销售医疗 设备产品、制造及销售塑料模具产品及制造、销售及分销数据媒体产品。于二零一一年十月,公司透过 收购Titron集团从而开拓制造及销售医疗设备产品、制造及销售塑料模具产品业务。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来源：金融界 财务数据显示，截至2024年12月31日，隽泰控股实现营业总收入3499.69万元，同比增长10.07%；归母 净利润-114.18万元，同比增长55.21%；毛利率36.89%，资产负债率62.26%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.87倍，行业中值0.4倍。隽泰控股 市盈率-36.1倍，行业排名第65位；其他京玖康疗（00648.HK）为0.38倍、巨星医疗控股（02393.HK） 为0.42倍、永胜医疗（01612.HK）为3.87倍、环球医疗（02666 ...

行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.47倍，行业中值0.33倍。巨星医 疗控股市盈率0.27倍，行业排名第1位；其他京玖康疗（00648.HK）为0.38倍、永胜医疗（01612.HK） 为3.87倍、环球医疗（02666.HK）为4.68倍、瑞慈医疗（01526.HK）为5.3倍、中国再生医学 （08158.HK）为6.94倍。 资料显示，巨星医疗控股有限公司是中国领先的高毛利医疗耗材及设备公司之一。集团立足于国内发展 蓬勃的医疗行业,其核心业务专注于高毛利的医疗耗材及设备,即医学影像产品和体外诊断产品。自成立 以来,集团以完善而具系统性的管理制度为后盾,在中国建立广大销售网络,赢得富士胶片、罗氏诊断、碧 迪及赛默飞世尔等国际知名厂商的信任。现时,集团为富士胶片在中国的医用胶片独家生产商,以及罗氏 诊断医疗体外诊断产品在中国最大的经销商之一。集团亦为富士胶片彩色相纸及工业影像产品在中国的 唯一生产商及独家经销商。除此之外,本集团以自家品牌'Yes!Star'制造及销售医疗齿科胶片。巨星医疗 将继续寻找有潜力的并购机会及与行业巨擘建立策略伙伴关系等战略,巩固其强大实力的医疗行业 ...

6月10日，截至港股收盘，恒生指数下跌0.08%，报24162.87点。加和国际控股（08513.HK）收报0.143 港元/股，上涨15.32%，成交量12万股，成交额1.72万港元，振幅0.81%。 来源：金融界 最近一个月来，加和国际控股累计跌幅11.43%，今年来累计跌幅29.94%，跑输恒生指数20.55%的涨 幅。 财务数据显示，截至2024年12月31日，加和国际控股实现营业总收入5565.65万元，同比增长14.33%； 归母净利润-1400.06万元，同比增长61%；毛利率2.18%，资产负债率75.71%。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.39倍，行业中值0.3倍。加和国际 控股市盈率-6.71倍，行业排名第83位；其他巨星医疗控股（02393.HK）为0.22倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为3.83倍、环球医疗（02666.HK）为4.7倍、瑞慈医疗 （01526.HK）为5.4倍。 机构评级方面，目前暂无机构对该股做出投资评级建议。 资料显示，加和国际控股有限公司为总部位於新加坡的合约制造商,制造及销售一 ...

Company Overview - MicroPort NeuroTech is a leading company in China's neuro-interventional medical device industry, recognized as the largest in the country, providing innovative solutions to doctors and patients [3] - Since the approval of its first product in 2004, the company has developed a portfolio of 30 commercialized products and candidates [3] Financial Performance - As of December 31, 2024, MicroPort NeuroTech achieved total revenue of 762 million yuan, representing a year-on-year growth of 14.44% [2] - The net profit attributable to shareholders was 254 million yuan, showing a significant increase of 74.63% year-on-year [2] - The gross margin stood at 72.98%, with a debt-to-asset ratio of 16.44% [2] Stock Performance - On June 3, the stock price of MicroPort NeuroTech closed at 12.26 HKD per share, marking an increase of 19.96% with a trading volume of 44.0165 million shares and a turnover of 513 million HKD [1] - Over the past month, the stock has experienced a cumulative decline of 6.41%, but it has risen by 18.7% year-to-date, outperforming the Hang Seng Index's increase of 15.44% [2] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -22.3 times, with a median of 0.29 times [3] - MicroPort NeuroTech's P/E ratio is 21.43 times, ranking 31st in the industry [3] - Comparatively, other companies in the sector have significantly lower P/E ratios, such as Giant Medical Holdings at 0.2 times and Jingjiu Health at 0.38 times [3]

财务数据显示，截至2024年12月31日，加和国际控股实现营业总收入5565.65万元，同比增长14.33%； 归母净利润-1400.06万元，同比增长61%；毛利率2.18%，资产负债率75.71%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 5月30日，截至港股收盘，恒生指数下跌1.2%，报23289.77点。加和国际控股（08513.HK）收报0.145港 元/股，上涨11.54%，成交量6万股，成交额8380港元，振幅11.54%。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-20.22倍，行业中值0.3倍。加和国际 控股市盈率-7.04倍，行业排名第82位；其他巨星医疗控股（02393.HK）为0.22倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为3.78倍、环球医疗（02666.HK）为4.64倍、瑞慈医疗 （01526.HK）为5.45倍。 最近一个月来，加和国际控股累计跌幅16.13%，今年来累计跌幅26.55%，跑输恒生指数17.51%的涨 幅。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来 ...

Company Overview - Meizhong Jiahe Medical Technology Development Group Co., Ltd. is a leading comprehensive oncology medical solution platform in China, focusing on advanced oncology diagnosis and treatment technology research, development, transformation, and application [4] - The company has attracted significant strategic investments from well-known institutions such as CICC Capital, CITIC Xingye, and Shenshan Asset, positioning itself as a mixed-ownership enterprise to promote the development and transformation of medical services in China [4] - Meizhong Jiahe operates multiple international oncology specialty medical institutions across major cities in China, ranking second among private oncology medical groups in terms of the number of owned medical institutions [4] Financial Performance - As of December 31, 2024, Meizhong Jiahe reported total operating revenue of 388 million yuan, a year-on-year decrease of 27.91%, and a net profit attributable to shareholders of -443 million yuan, a year-on-year decrease of 18.8% [2] - The company's gross margin stands at -17.32%, with a debt-to-asset ratio of 67.82% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Meizhong Jiahe's stock [3] - The company's price-to-earnings (P/E) ratio is -9.38, ranking 76th in the healthcare equipment and services industry, which has an average P/E ratio of -20.22 [3] Business Model and Services - Meizhong Jiahe provides comprehensive oncology medical services, including diagnosis and treatment solutions, operational management, equipment leasing, and maintenance services [4] - The company has developed a cloud-based business model to empower enterprise clients, particularly in lower-tier cities, through remote consultation, quality control, supply chain management, and joint research [4][5] - The company has launched platforms such as "Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform" and "Jiahe Feiyun Intelligent Radiotherapy Cloud Platform" to enhance the quality of oncology diagnosis and treatment in underserved areas [4] Technological Advancements - Meizhong Jiahe has strong technical capabilities in radiation therapy, having hosted the first guideline project approved by the National Cancer Center's Radiation Quality Control Expert Committee led by a private medical institution [5] - The company has received approval for additional guidelines related to radiation therapy data auditing and remote treatment planning, further solidifying its expertise in the field [5]

Company Overview - Green International Holdings Limited is an investment holding company primarily engaged in providing healthcare and medical services, beauty and fitness services, and comprehensive financial services including lending, securities brokerage, and asset management [2]. Financial Performance - As of December 31, 2024, Green International Holdings reported total revenue of 49.0894 million, representing a year-on-year growth of 8.56% [1]. - The company recorded a net profit attributable to shareholders of -0.7473 million, showing a significant year-on-year improvement of 92.41% [1]. - The gross profit margin stood at 59.8%, while the debt-to-asset ratio was 59.73% [1]. Stock Performance - As of May 27, the stock price of Green International Holdings closed at 0.6 HKD per share, marking an increase of 31.87% with a trading volume of 120,200 shares and a turnover of 68,100 HKD [1]. - Over the past month, the stock has experienced a cumulative decline of 20.18%, while year-to-date, it has increased by 12.35%, underperforming the Hang Seng Index by 16.06% [1]. Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -19.72 times, with a median of 0.3 times [1]. - Green International Holdings has a P/E ratio of -372.06 times, ranking 53rd in the industry [1]. - Comparatively, other companies in the sector have the following P/E ratios: Giant Medical Holdings at 0.23 times, Jingjiu Health at 0.38 times, Yongsheng Medical at 3.97 times, Global Medical at 4.58 times, and China Regenerative Medicine at 5.14 times [1].